Extracellular vesicles in atherosclerosis cardiovascular disease: emerging roles and mechanisms

Several human studies show positive signals, while research methods and sample sizes continue to develop.

• Level A · Stronger Clinical Evidence
• Level B · Emerging clinical evidence with positive signals
• Level C · Early human research exploring benefits
• Level D · Scientific groundwork from lab and animal studies
• Emerging · Emerging topic under active research

Abstract (original English)

The pathogenesis of atherosclerotic cardiovascular disease is complex, involving multiple cell types and biological processes. Extracellular Vesicles (EVs) are small, cell-derived particles increasingly recognized for their role in cardiovascular diseases. EVs are believed to play key roles in this context by promoting inflammation, regulating intercellular communication, and influencing lipid metabolism. As a crucial mediators of cell communication, EVs contribute to both the progression of atherosclerosis (AS) and plaques stability. Although research on the role of EVs in AS and the role of biomarkers or drug carriers in clinical practice has been expanding, several challenges remain for clinical applications, including the lack of specific therapeutic targets for EVs, flaws in the separation and purification processes, and limited clinical trial data on their safety. This review provides a comprehensive overview of the function of EVs in AS and recent advances in their diagnostic and therapeutic potential, aiming to inform future clinical applications.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.